Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis

Phototherapy for sclerosing skin conditions

“…This was similar Review to findings reported by Von Kobyletzki et al [39]. Morita et al reported improvement using medium-dose UVA1 (60 J/cm 2 ) on the hands and forearms of four patients with a range of nine to 29 sessions [40]. Marked softening was noted in all four patients and there was a significant increase in joint passive range of motion, skin temperature and cutaneous elasticity (all with p values < 0.05).…”

Dose-Response and Time-Course Characteristics of UV-A1 Erythema

“…At the 8-hour time point for subjects with skin types I and II, the reading from the inner arm did not significantly correlate with the reading from the back (r s =0.432; P=. 16), but at the 24-hour (r s =0.713; P=.01) time point, good correlation was seen ( Figure 5).…”

“…More recently, higher output sources have been developed, allowing for higher dose delivery within a practical exposure time. 11 On this basis, "high-dose" UV-A1 therapy has been used for the effective treatment of atopic dermatitis, 12-15 scleroderma, 16,17 and several other skin diseases. [18][19][20][21] The effect appears to be local, and therefore treatment of isolated plaques of scleroderma would limit the potential adverse effects of treatment, while targeting the therapeutic action.…”

Phototherapy in Pediatric Dermatology

“…Uygulama sırasında özel bir ekipman, yöntem ve klima sistemi gerektirdiği için kullanımı zor ve sınırlıdır. Daha uzun dalga boyu sebebiyle UVA1 radyasyon daha derine penetre olabilmektedir 8,9 . Uzun yıllardır özellikle psoriasis tedavisinde tek başına ve kombinasyon tedavilerinin bir parçası olarak kullanılmakta olan genişbant UVB tedavisinin 311 nm dalga boyu odaklı formu olan darbant UVB tedavisi, fototerapideki önemli aşamalardan biridir.…”